Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com

MONTREAL, Jan. 30, 2017 /PRNewswire/ -- IntelGenx Technologies Corp. (OTCQX: IGXT), based in Montreal, focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm(TM) technology platform, today announced that Executive Vice President and CFO, Andre Godin will present live at VirtualInvestorConferences.com on February 2, 2017.

DATE: Thursday, February 2, 2017
TIME: 1:45 p.m. EST
LINK: http://tinyurl.com/201prepr

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Learn more about the event at www.VirtualInvestorConferences.com.

Recent Company Highlights


    --  In December 2016 IntelGenx signed a definitive agreement with Chemo
        Group for the co-development and commercialization of a generic tablet
        in the area of CNS (central nervous system)
    --  In December 2016 IntelGenx entered into a co-development and
        commercialization agreement with Endo for a new product utilizing
        IntelGenx' proprietary VersaFilm(TM) for the USA market
    --  In December 2016 IntelGenx signed an exclusive license agreement with
        Pharmatronic Co. for the commercialization of RIZAPORT® in the Republic
        of Korea (South Korea). RIZAPORT® is a proprietary oral thin film
        formulation of rizatriptan for the treatment of acute migraines
    --  In November 2016 IntelGenx signed a binding term sheet for a license to
        Eli Lilly tadalafil erectile dysfunction dosing patent, United States
        Patent No. 6,943,166 (the '166 dosing patent)

About IntelGenx Technologies Corp.

IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm(TM) technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.

IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the-art manufacturing facility, established for the VersaFilm(TM) technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients.

For more information, please visit our website at http://www.intelgenx.com/

About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intelgenx-to-webcast-live-at-virtualinvestorconferencescom-february-2-300398629.html

SOURCE IntelGenx Technologies Corp.